Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
See detailDosage sérique des antimycosiques azolés
MISTRETTA, Virginie ULg; Charlier, Corinne ULg

Conference (2012, November 13)

Detailed reference viewed: 15 (5 ULg)
Full Text
Peer Reviewed
See detailLe dosage urinaire et plasmatique du NGAL: étude analytique et implications pratiques pour le clinicien
Cavalier, Etienne ULg; Rozet, Eric ULg; Bekaert, Anne-Catherine ULg et al

in Néphrologie & Thérapeutique (2010, September), 6(5), 350

Detailed reference viewed: 67 (3 ULg)
Full Text
See detailDosages de la PTH et de la vitamine D: en est-on enfin au bout du tunnel?
CAVALIER, Etienne ULg

Conference (2011, September 30)

Detailed reference viewed: 13 (5 ULg)
See detailDosages quantitaifs de principes actifs dans les formes solides par spectroscopie proche infrarouge: Application pratique au test d'uniformité de teneur des comprimés
Ginot, Yves-Michel; Bernard-Moulin, Patrick; Boiret, Mathieu et al

Conference (2013, October 03)

L'augmentation du nombre de dosages à réaliser dans l'industrie pharmaceutique conduit à rechercher des méthodes alternatives. La spectroscopie proche infrarouge répond précisément à cette demande en ... [more ▼]

L'augmentation du nombre de dosages à réaliser dans l'industrie pharmaceutique conduit à rechercher des méthodes alternatives. La spectroscopie proche infrarouge répond précisément à cette demande en permettant des dosages rapides, non destructifs et respectueux de l'environnement. Le texte publié dans SFSTP Pharma Pratiques en 2010 énonçait la méthodologie à suivre pour développer une technique de dosage de substance active dans une formulation solide de type comprimé par spectroscopie proche infrarouge. Il est apparu intéressant d'illustrer et de compléter les différentes étapes de cette méthodologies au travers d'exemples. [less ▲]

Detailed reference viewed: 75 (2 ULg)
Full Text
See detailDosages radioimmunologiques
Beckers, Jean-François ULg; Ectors, Francis ULg

Poster (1978, March)

Detailed reference viewed: 74 (3 ULg)
Full Text
See detailDosages réalisables pour le diagnostic de gestation
Melo de Sousa, Noelita ULg; El Amiri, B.; Sulon, J. et al

in Journées Européennes de la Société Française de Buiatrie 2002 (2002)

Lorsque les signaux embryonnaires de la gestation induisent une modification du côté maternel, une possibilité nouvelle s’ouvre aux chercheurs attentifs au développement de tests pour le diagnostic ou le ... [more ▼]

Lorsque les signaux embryonnaires de la gestation induisent une modification du côté maternel, une possibilité nouvelle s’ouvre aux chercheurs attentifs au développement de tests pour le diagnostic ou le suivi de la gestation. Dans ce chapitre, nous essayerons de passer en revue les différentes molécules dont le dosage ou la mise en évidence a fait l’objet de publications scientifiques en relation avec le diagnostic de la gestation. Dans la mesure du possible, nous envisagerons les différents marqueurs en suivant la chronologie de leur apparition au cours de la gestation, mais ce critère ne prendra pas un caractère absolu car souvent plusieurs molécules se recouvrent, ou encore leur apparition au niveau de placenta précède largement le moment où elles apparaissent dans le sang maternel en quantités mesurables. Nous essayerons également, de connecter chaque molécule avec l’application que son dosage permet dans la clinique vétérinaire. Pour terminer, nous ferons une description rétrospective de quelques cas cliniques bien documentés qui montrent l’importance de l’association du dosage de protéines associées à la gestation et de la progestérone pour arriver à une meilleure compréhension des échecs observés dans le déroulement de la gestation. [less ▲]

Detailed reference viewed: 14 (2 ULg)
Full Text
Peer Reviewed
See detailA dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study
Durez, P.; Van den Bosch, F.; Corluy, L. et al

in Rheumatology (2005), 44(4), 465-468

Objectives. To analyse the effect of a dose increase in patients with severe rheumatoid arthritis (RA) with insufficient clinical response to 3 mg/kg infliximab every 8 weeks. Methods. Patients suffering ... [more ▼]

Objectives. To analyse the effect of a dose increase in patients with severe rheumatoid arthritis (RA) with insufficient clinical response to 3 mg/kg infliximab every 8 weeks. Methods. Patients suffering from active refractory RA despite methotrexate, were treated with i.v. infusions of infliximab (3 mg/kg) on week 0, 2, 6 and every 8 weeks thereafter. Based on the clinical judgement at week 22, patients received a dose increase of 100 mg from week 30 on. The American College of Rheumatology (ACR) core set for disease activity measures was regularly assessed. Results. Five hundred and eleven RA patients were included. At week 22, 61.4, 34 and 14.1% of all patients met ACR 20, ACR 50 and ACR 70 criteria, respectively, and 6.1% of patients were in remission. A low swollen joint count at baseline was correlated with improvement at week 22 for ACR 20 (P < 0.06), ACR 50 (P < 0.06) and ACR 70 (P < 0.005). The change in HAQ score between weeks 0 and 22 was predictive for response at week 54 (P < 0.01). The dose of infliximab was increased by 100 mg in 22% of the patients. Most baseline values of patients requiring dose increase were higher (P <= 0.001) than the baseline values of the remaining patients. Increasing the dose of infliximab by one vial from week 30 on could circumvent the partial loss of response in these patients. Conclusion. Infliximab use in this large out-patient cohort resulted in a significant clinical improvement. A subgroup that partially lost response during the first 22 weeks could regain response by adding 100 mg of infliximab to the subsequent doses. Due to the current study design, however, a regression to the mean like effect could not be ruled out. [less ▲]

Detailed reference viewed: 13 (1 ULg)
Peer Reviewed
See detailDose-dependent caffeine-induced conditioned locomotion in mice
Pirona, Alexandre; Ferrara, André Onofrio; Tirelli, Ezio ULg

in Behavioural Pharmacology (2001), 12

Detailed reference viewed: 18 (3 ULg)
Full Text
Peer Reviewed
See detailDose-dependent effect of experimental Schmallenberg virus infection in sheep
Poskin, A; Martinelle, Ludovic ULg; Mostin, L et al

in Veterinary Journal (in press)

Detailed reference viewed: 18 (5 ULg)
Full Text
Peer Reviewed
See detailDose-dependent modulation of choroidal neovascularization by plasminogen activator inhibitor type 1: Implications for clinical trials
Lambert, Vincent ULg; Munaut, Carine ULg; Carmeliet, Peter et al

in Investigative Ophthalmology & Visual Science (2003), 44(6), 2791-2797

PURPOSE. To explain the conflicting reports about the influence of plasminogen activator inhibitor type (PAI-1) on pathologic angiogenesis, such as occurs during the exudative form of age-related macular ... [more ▼]

PURPOSE. To explain the conflicting reports about the influence of plasminogen activator inhibitor type (PAI-1) on pathologic angiogenesis, such as occurs during the exudative form of age-related macular degeneration. METHODS. The expression of PAI-1 mRNA was analyzed in human and murine choroidal neovascularization (CNV) by RTPCR. The influences of increasing doses of recombinant PAI-1 were evaluated by daily intraperitoneal injections in PAI-1-1-and wild-type animals with a model of laser-induced CNV. The double mechanism of action of PAI-1 (proteolytic activity inhibition versus vitronectin binding) was explored by immunohistochemical localization of fibrinogen/fibrin and by injection of recombinant PAI-1 protein defective for vitronectin binding or with adenoviral vectors bearing a mutated binding-deficient PAI-1 gene. RESULTS. PAI-1 expression was present in human CNV and strongly induced in the course of experimental subretinal neovascularization. Daily injections of recombinant PAI-1 proteins in control and PAI-1(-/-) animals demonstrated that PAI-1 could exhibit both pro- and antiangiogenic effects, dependent on the dose. PAI-1 mutants defective for vitronectin binding were used to show that PAI-1 promotes choroidal pathologic angiogenesis merely through its antiproteolytic activity. CONCLUSIONS. These observations may help to reconcile reports with opposite results regarding the effects of PAI-1 on angiogenesis and certainly warn against uncontrolled use of PAL I modulating drugs in clinical trials. [less ▲]

Detailed reference viewed: 33 (4 ULg)
Full Text
Peer Reviewed
See detailDose-dependent RNAi-mediated geminivirus resistance in the tropical root crop cassava.
Vanderschuren, Hervé ULg; Alder, Adrian; Zhang, Peng et al

in Plant molecular biology (2009), 70(3), 265-72

Cassava mosaic disease is a major constraint for cassava production in Africa, resulting in significant economic losses. We have engineered transgenic cassava with resistance to African cassava mosaic ... [more ▼]

Cassava mosaic disease is a major constraint for cassava production in Africa, resulting in significant economic losses. We have engineered transgenic cassava with resistance to African cassava mosaic virus (ACMV), by expressing ACMV AC1-homologous hairpin double-strand RNAs. Transgenic cassava lines with high levels of AC1-homologous small RNAs have ACMV immunity with increasing viral load and different inoculation methods. We report a correlation between the expression of the AC1-homologous small RNAs and the ACMV resistance of the transgenic cassava lines. Characterization of the small RNAs revealed that only some of the hairpin-derived small RNAs fall into currently known small interfering RNA classes in plants. The method is scalable to stacking by targeting multiple virus isolates with additional hairpins. [less ▲]

Detailed reference viewed: 8 (0 ULg)
Full Text
Peer Reviewed
See detailA Dose-Effect Relationship For Deltaretrovirus-Dependent Leukemogenesis In Sheep
Pomier, Carole; Alcaraz, Maria Teresa Sanchez; Debacq, Christo^phe et al

in Retrovirology (2009), 6

Detailed reference viewed: 36 (20 ULg)
Full Text
Peer Reviewed
See detailDose-related bone effects of strontium ranelate in postmenopausal women
Meunier, P. J.; Reginster, Jean-Yves ULg

in Osteoporosis International (2002), 13(S1), 153

Detailed reference viewed: 5 (2 ULg)
Peer Reviewed
See detailDose-Response and Pharmacokinetic Study with Almitrine Bismesylate after Single Oral Administrations in Copd Patients
Bury, Thierry ULg; Jeannot, J. P.; Ansquer, J. C. et al

in European Respiratory Journal : Official Journal of the European Society for Clinical Respiratory Physiology (1989), 2(1), 49-55

To better define the dose-effect relationship and the pharmacokinetics of almitrine, sixteen stable hypoxaemic COPD patients received random single oral administrations of almitrine bismesylate 50, 100 ... [more ▼]

To better define the dose-effect relationship and the pharmacokinetics of almitrine, sixteen stable hypoxaemic COPD patients received random single oral administrations of almitrine bismesylate 50, 100 and 150 mg or placebo at two-week intervals in a double-blind manner. Resting ventilation, arterial blood gases and plasma almitrine levels were measured. No significant changes were seen after placebo administration. Almitrine 50 and 100 mg caused a significant dose-related improvement in arterial oxygen tension (PaO2) in thirteen of the sixteen patients. Almitrine 150 mg caused little if any additional PaO2 increment. PaO2 returned to near basal values after 24 h. Two patients responded to almitrine 100 and 150 mg only, whereas one patient did not respond at all. Mean PaO2 increases in the sixteen patients were 0.9 kPa (7 mmHg), 1.5 kPa (11 mmHg) and 1.6 kPa (12 mmHg) 3 h after 50, 100 and 150 mg, respectively. A significant mean 0.9 kPa (7 mmHg) decrease in arterial carbon dioxide tension (PaCO2) and a l.min-1 increase in ventilation were observed after almitrine 150 mg. Mean maximum almitrine plasma concentration and area under the curve correlated linearly with dose. The relationship between mean PaO2 improvement and mean almitrine plasma level was curvilinear with a flattening of the curve over plasma levels of 150 ng.ml-1. Almitrine plasma half-life was found to be 116-140 h. [less ▲]

Detailed reference viewed: 5 (0 ULg)
Peer Reviewed
See detailDose-response curve for torasemide in healthy volunteers.
Scheen, André ULg

in Arzneimittel Forschung (1988), 38(1A), 156-9

The safety and diuretic activity of torasemide (1-isopropyl-3- ([4-(3-methyl-phenylamino)pyridine]-3-sulfonyl)urea) were investigated in a phase I single-blind clinical study. After a pretreatment control ... [more ▼]

The safety and diuretic activity of torasemide (1-isopropyl-3- ([4-(3-methyl-phenylamino)pyridine]-3-sulfonyl)urea) were investigated in a phase I single-blind clinical study. After a pretreatment control day on placebo, a single dose of torasemide was administered orally according to an escalating dosage of 2.5, 5, 10 and 20 mg, respectively, in 4 groups of 3 healthy young male volunteers, after an overnight fast and 1 h before breakfast. The peak stimulatory effect on urinary volume was observed within 1 to 2 h and was followed by a gradual decline at the 3rd or 4th h back to or even slightly below the corresponding control values. Thus, the duration of action averaged 3-4 h and only moderate rebound effects were detected. This time-related diuretic activity perfectly fitted with the pharmacokinetics data since torasemide plasma levels peaked at the 1st h after drug administration and thereafter rapidly fell to less than 10% of the maximal plasma concentrations after the 4th h. While 2.5 mg torasemide showed only minor diuretic action, urinary volume and urinary excretion of sodium, chloride and calcium increased linearly with the logarithm of the dose during the first 4 h as well as during the whole 24 h period with 5, 10 and 20 mg torasemide. Conversely, the urinary density and osmolality fell progressively as the dose of torasemide increased. There was a trend towards a moderate decrease in urinary excretion of uric acid which seemed independent of the dose given. Finally, only minimal potassium urinary losses were observed without clear tendency towards an increase with increasing drug doses.(ABSTRACT TRUNCATED AT 250 WORDS) [less ▲]

Detailed reference viewed: 26 (0 ULg)
Peer Reviewed
See detailDose-response relationship between plasma oxytocin and ACTH concentrations during oxytocin infusion in normal men
Legros, Jean-Jacques ULg; Chiodera, Paolo; Geenen, Vincent ULg et al

in Journal of Clinical Endocrinology and Metabolism (1984), 58

Detailed reference viewed: 9 (0 ULg)